Asahi Kasei (JP:3407) has released an update.
Asahi Kasei Corporation reports a year-on-year increase in operating income across all segments for Q1 2024, driven by a significant recovery in electronics and semiconductor markets, alongside stable performance in Homes and Health Care sectors. The company maintains its FY 2024 interim dividend at ¥18 per share and announces a tender offer for Swedish pharmaceutical company Calliditas Therapeutics AB. Despite an uncertain operating environment, Asahi Kasei is revising its H1 2024 forecasts upward, with a particular emphasis on Material and Health Care sectors, and is focusing on enhancing profitability through structural business transformations.
For further insights into JP:3407 stock, check out TipRanks’ Stock Analysis page.
